Table 1.
Patient characteristics.
| Patient | 1 | 2 | 3 | 4 | 5 |
| Patient age/disease discovery (year) | 55 | 33 | 63 | 44 | 43 |
| Primary disease date | April 1981 | August 1985 | January 1984 | January 1997 | August 1993 |
| Primary disease location | Right ankle | Left calf | Left ankle | Left arm | Left thorax |
| Clarck index | III | V | IV | III | III |
| First recurrence date | March 1988 | June 1986 | April 1987 | January 1997 | March 1998 |
|
Previous treatment for advanced disease (before cystemustine) |
None | Dacarbazine Vindesine (6 cycles) Dacarbazine Vinblastine (6 cycles) Dacarbazine Interferon α 2a (6 cycles) |
Interferon α 2a Radiotherapy | None | Dacarbazine (8 cycles) |
| Treatment start date | March 1988 | May 1990 | August 1990 | February 1997 | Novembre 1998 |
| Custemustine dose (mg/m2) | 90 | 60 | 90 | 90 | 60 |
| Metastatic sites | Popliteal mass Lymph node | Lung Bone | Lymph node | Lymph node Sub-cutaneous | Lung |
| Treatment concomitant to Cystemustine | Surgery (March 1988) | None | None | None | None |
| Recurrence of the disease | None | None | None | None | None |
| Date of death | November 2000 | Alive | March 2000 | Alive | Alive |
| Disease free survival (years) | 12 | 14 | 10 | 7 | 6 |